A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
The issuer announced a $7.5 million Seed+ round without naming the strategic lead or London investor. BlueRun’s role in2021 should not be transferred to the2026 round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
Program / service
Target / indication
Representative stage
Evidence & scope
Cyclic peptide discovery and partnering platform
Not disclosed · Not disclosed
未披露
No human oral results confirmed
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
20n Bio announced $7.5 million in Seed+ financing to advance AI-enabled cyclic peptide discovery, screening workflows, and its therapeutic pipeline. The company identifies oral peptides among potential applications but has not disclosed a validated clinical oral cyclic peptide candidate or human oral pharmacokinetics. The strategic lead investor was unnamed; investors from earlier rounds should not be assigned to this financing.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
